anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Previous studies have identified VETC as a new metastatic pattern independent of EMT that may be associated with immunosuppression as well as poor prognosis. Multiple retrospective studies find higher rates of postoperative recurrence, distant metastasis in VETC-positive patients. How to improve surgical prognosis in VETC-positive patients needs to be explored. In recent years, adjuvant immunotherapy (sintilimab) and adjuvant immunotherapy combined with targeted therapy (T+A) have been shown to be effective in improving the surgical prognosis. There are no published studies on how to improve prognosis for VETC-positive population. One of our unpublished retrospective studies found that VETC-positive patients receiving PD-1 monoclonal antibody was not effective in improving prognosis, however, PD-1 inhibitor combined with lenvatinib reduces recurrences significantly. In addition, some studies have also found that postoperative adjuvant hepatic artery infusion chemotherapy (HAIC) is also potentially useful in improving surgical prognosis. It is not clear whether triple therapy can further reduce recurrence in these tumors, which have highly aggressive characteristics.
WEGOVY (semaglutide) injection, for subcutaneous use, contains semaglutide, a human GLP-1 receptor agonist (or GLP-1 analog). The peptide backbone is produced by yeast fermentation. The main protraction mechanism of semaglutide is albumin binding, facilitated by modification of position 26 lysine with a hydrophilic spacer and a C18 fatty di-acid. Furthermore, semaglutide is modified in position 8 to provide stabilization against degradation by the enzyme dipeptidyl-peptidase 4 (DPP-4). A minor modification was made in position 34 to ensure the attachment of only one fatty di-acid. The molecular formula is C187H291N45O59 and the molecular weight is 4113.58 g/mol.

     Figure 1. Structural Formula of Semaglutide

WEGOVY is a sterile, aqueous, clear, colorless solution. Each 0.5 mL single-dose pen contains a solution of WEGOVY containing 0.25 mg, 0.5 mg or 1 mg of semaglutide; and each 0.75 mL single-dose pen contains a solution of WEGOVY containing 1.7 or 2.4 mg of semaglutide. Each 1 mL of WEGOVY contains the following inactive ingredients: disodium phosphate dihydrate, 1.42 mg; sodium chloride, 8.25 mg; and water for injection. WEGOVY has a pH of approximately 7.4. Hydrochloric acid or sodium hydroxide may be added to adjust pH.
Impairments following stroke make it one of the leading causes of disability. Many individuals with stroke do not recover complete function of the upper limb at time of discharge from clinical services. Moreover, early stage improvements may wane following the cessation of formal therapies. Regaining as much upper limb function as possible is important, as even mild impairments are associated with limitations in daily function and lower health-related quality of life. The overarching purpose of this project is to use portable technology, affordable for home use, to provide objective feedback on performance of upper limb motor tasks to individuals with residual deficits following chronic conditions such as stroke. Objective feedback serves to better inform the participant of their progress and actively engage them in their rehabilitation, thus encouraging self-management of rehabilitation. Results from a recent survey shows therapists predominantly provide patients with stroke written home exercise programs at time of discharge from therapies. With this static approach, patients have a limited capacity to evaluate their motor performance and no encouragement to refine their movement. Smartphones were coupled with three-dimensional (3D) printed objects to create a home rehabilitation system, mRehab. The built-in sensors in smartphones and a custom app can quantify characteristics of movement and provide actionable feedback to users during in-home rehabilitation. It was hypothesized that 1) participants with stroke could use mRehab in a home program with minimal oversight and 2) use of mRehab would result in changes in functional movement.

Methodology: A single-subject experimental design with multiple baselines was used. A strength of the single-subject study design is that participants serve as their own control. Each participant had a varying length of the baseline and follow-up periods to establish that the intervention, rather than time, was the primary reason for any observed change in performance. Participants completed baseline measurements, a six-week mRehab home program, and follow-up measurements. Baseline measurements consisted of both in-lab and in-home measurements. Participants attended two lab visits prior to starting the home program to establish baselines on clinical assessments and to learn how to use mRehab. MRehab collected limited preliminary performance data without providing feedback during baseline. Participants then used mRehab in a six week home program receiving feedback on their performance each time they completed practice of an activity. At the completion of the home program participants completed follow up assessments that were similar to the baseline measurements. In addition, usability of mRehab was assessed.
The invention provides an immunostimulant and anti-virus composition used for animals, so as to better play the effects of inhibiting the in vivo and in vitro virus propagation, protecte the cells from being infected and improve the survival rate of the infected animals of traditional Chinese medicine polysaccharide. The immunostimulant and anti-virus composition for animals contains 1 to 9 portions by weight of effective ingredient astragalus polysaccharide and 1 to 9 portions by weight of indigowoad root polysaccharide. The invention consists of 4 to 30 portions by weight of effective ingredients and 70 to 96 portions by weight of carriers. The carrier is at least one of anhydrous glucose, sodium bicarbonate and sodium chloride. The carrier is the water for injection. Any one immunostimulant and anti-virus composition for animals can be applied in prevention and treatment of virus infectious diseases and low immunity of livestock, poultry and pets. The invention mainly extracts the polysaccharide ingredients from the traditional Chinese medicines of astragalus and indigowoad root, the two polysaccharides are mixed for usage, so the effect is better than any individual; the invention is the first time that the invention can not only be used as the immunostimulant, but can also used as the anti-virus drug.
Patients receive gallium Ga 68-labeled PSMA-11 IV over 1-2 minutes. After about 60 minutes, patients undergo PET/MRI for approximately over 50-60 minutes. Patients may undergo an optional repeat gallium Ga 68-labeled PSMA-11 PET between 8 and 12 weeks after completion of the first PET/MRI.
PROBLEM TO BE SOLVED: To allow a single device to easily execute DDS targeting at the site of the diagnosing while executing ultrasonic diagnosis of the same degree as a conventional device. SOLUTION: The device is provided with collecting means 12, 21 to 23 collecting a received signal according to the echo signal of a first ultrasonic signal, picture obtaining means 24, 25, 26, 28 for obtaining picture information by processing the echo signal, irradiating means 12, 21 transmitting a second ultrasonic signal for activating medicine dosed to an examinee to the examinee. The picture information is information on the tomographic picture of the cross section of the examinee, information of the picture of a blood stream, etc. The collecting means are provided with a probe 12, a transmission part 21 transmitting the first ultrasonic signal through the probe 12 and a receiving part 22 receiving the echo signal through the probe 12. The irradiating means transmits a second ultrasonic signal by using the part 21 and the probe 12 in common. Means 31 to 33 controlling the forms of the transmitting order of the transmission of the first and second ultrasonic signal are provided.
A facility stores a person's personal information (“PI”) on a portable storage device (“PSD”) of the person. In some cases, the PSD bears a fax number mapping uniquely to the person; when a fax containing the person's PI is sent to this fax number, the facility stores an encrypted version of the PI on a relay server (“RS”). When the PSD connects with an access device, the encrypted version of the PI is retrieved from the RS and stored on the PSD. In some cases, the PSD bears a non-textual visual symbol; when its images is captured by a device such as a smartphone, an identifier encoded in the symbol is used to transmit encrypted PI to the RS. In some cases, each access device reports aggregates of personal data to an analysis server. In some cases, the facility statistically obfuscates these aggregates for transmission to/storage on the analysis server.
Renal impairment, including cases of acute renal failure and Fanconi syndrome, has been reported when cobicistat, a component of PREZCOBIX, was used in an antiretroviral regimen that contained tenofovir DF. Co-administration of PREZCOBIX and tenofovir DF is not recommended in patients who have an estimated creatinine clearance below 70 mL/min [see Dosage and Administration (2.3)] . 

  * Document urine glucose and urine protein at baseline [see Dosage and Administration (2.2)] and perform routine monitoring of estimated creatinine clearance, urine glucose, and urine protein during treatment when PREZCOBIX is used with tenofovir DF. Measure serum phosphorus in patients with or at risk for renal impairment when used with tenofovir DF. 
  * Co-administration of PREZCOBIX and tenofovir DF in combination with concomitant or recent use of a nephrotoxic agent is not recommended.



See cobicistat full prescribing information for additional information regarding cobicistat.
The study group will be supplemented with DHA and AA emulsion for 28 days. Patients will be followed up until hospital discharge. The emulsion will be administered by nasogastric or orogastric tube together with the scheduled milk intake (from the bank or the mother's own with a differentiated amount of supplementation depending on the type of milk administered and the infant's weight).
After surgery or trauma, scar tissues would form during the healing process. However, hypertrophic scars and keloids might happen to some patients, both of which are often pruritic and erythematous. Besides, the markedly elevated tumor-like appearance usually brings much concern to patients. Moreover, significant pain or discomfort could happen to keloids. Various treatment strategies were mentioned but without a solid solution to all of the scars. Investigators hope to evaluate the differences of scar volume, appearance and symptoms (itching and pain) in participants receiving simultaneous intralesional injection of Botulinum toxin type A and/or steroids. Besides, side effects would also be recorded. Investigators hope to establish a more effective intralesional injection therapy for participatns suffering from hypertrophic scars and keloids.
The Brigham and Women's Pain Management Center is conducting a research study for chronic pelvic pain patients due to endometriosis. The study will assess the effect of electro-stimulation for the treatment of Chronic Pelvic Pain. You may be eligible if you have chronic pelvic pain due to endometriosis, are between the ages of 21- 64, and not taking opioid medication (such as morphine or oxycodone). The study will require two visits, each lasting about 2 hours. The study takes place at the Brigham \& Women's Pain Management Center, 850 Boylston St., Chestnut Hill. Please contact Chrissie Cahalan at 617-732-9014 or ccahalan1@partners.org if interested.

Vitaly Napadow, Ph.D., Lic.Ac. Assistant Professor Dept. of Radiology, Massachusetts General Hospital, Harvard Medical School
BACKGROUND: Ornithine Transcarbamylase Deficiency (OTCD) is an X-linked urea cycle disorder characterized by acute hyperammonemic episodes. Hemizygous males are usually affected by a severe/fatal neonatal-onset form or, less frequently, by a late-onset form with milder disease course, depending on the residual enzymatic activity. Hyperammonemia can occur any time during life and patients could remain non- or mis-diagnosed due to unspecific symptoms. In heterozygous females, clinical presentation varies based on the extent of X chromosome inactivation. Maternal transmission in X-linked disease is the rule, but in late-onset OTCD, due to the milder phenotype of affected males, paternal transmission to the females is possible. So far, father-to-daughter transmission of OTCD has been reported only in 4 Japanese families.
RESULTS: We identified in 2 Caucasian families, paternal transmission of late-onset OTCD with severe/fatal outcome in affected males and 1 heterozygous female. Furthermore, we have reassessed the pedigrees of other published reports in 7 additional families with evidence of father-to-daughter inheritance of OTCD, identifying and listing the family members for which this transmission occurred.
CONCLUSIONS: Our study highlights how the diagnosis and pedigree analysis of late-onset OTCD may represent a real challenge for clinicians. Therefore, the occurrence of paternal transmission in OTCD should not be underestimated, due to the relevant implications for disease inheritance and risk of recurrence.
Hypersensitivity Reactions

Serious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir, a component of TRIUMEQ and TRIUMEQ PD (abacavir, dolutegravir, and lamivudine). Patients who carry the HLA‑B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir, although hypersensitivity reactions have occurred in patients who do not carry the HLA‑B*5701 allele [see Warnings and Precautions (5.1)].

TRIUMEQ and TRIUMEQ PD are contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA‑B*5701-positive patients [see Contraindications (4), Warnings and Precautions (5.1)]. All patients should be screened for the HLA‑B*5701 allele prior to initiating therapy with TRIUMEQ or TRIUMEQ PD or reinitiation of therapy with TRIUMEQ or TRIUMEQ PD, unless patients have a previously documented HLA‑B*5701 allele assessment. Discontinue TRIUMEQ or TRIUMEQ PD immediately if a hypersensitivity reaction is suspected, regardless of HLA‑B*5701 status and even when other diagnoses are possible [see Contraindications (4), Warnings and Precautions (5.1)]. 

Following a hypersensitivity reaction to TRIUMEQ or TRIUMEQ PD, NEVER restart TRIUMEQ or TRIUMEQ PD or any other abacavir‑containing product because more severe symptoms, including death can occur within hours. Similar severe reactions have also occurred rarely following the reintroduction of abacavir-containing products in patients who have no history of abacavir hypersensitivity [see Warnings and Precautions (5.1)].

Exacerbations of Hepatitis B

All patients with HIV-1 should be tested for the presence of hepatitis B virus (HBV) prior to or when initiating TRIUMEQ or TRIUMEQ PD. Emergence of lamivudine-resistant HBV variants associated with lamivudine-containing antiretroviral regimens has been reported. If TRIUMEQ or TRIUMEQ PD is used in patients co-infected with HIV-1 and HBV, additional treatment should be considered for appropriate treatment of chronic HBV; otherwise, consider an alternative regimen.

Severe acute exacerbations of hepatitis B have been reported in patients who are co‑infected with HBV and HIV-1 and have discontinued lamivudine, a component of TRIUMEQ and TRIUMEQ PD. Closely monitor hepatic function in these patients and, if appropriate, initiate anti-HBV treatment [see Warnings and Precautions (5.2)].
The Ministry of Health (MIH) in Rwanda has planned to provide Brilliance devices (phototherapy) to 46 public hospitals in Rwanda. The investigators have worked with MIH to have the delivery of these machines be staggered over three phases through random selection. The methodology relies on the staggered distribution of Brilliance devices and survey data collected prior and during delivery dates to evaluate the provision of low-cost high quality phototherapy machines, following the basic design of a staggered randomized controlled trial. Specifically, the investigators will survey all hospitals prior to the receipt of any Brilliance devices to provide a baseline description of the care received in these facilities. These surveys will collect information on the facility itself, including average infant jaundice caseloads and descriptions of recent cases. The investigators will then randomly select 15 hospitals to receive the Brilliance units. Three months after installation of Brilliance has occurred at these facilities (Group 1), another randomly selected subset of 16 facilities (Group 2) will receive their Brilliance machines. Three months after these installations have been completed, the remaining facilities (Group 3) will receive their Brilliance machines. During this period, there will be ongoing data collection from the hospitals, creating a panel dataset on the jaundice-related caseloads at these facilities. The data collected will be akin to collecting hospital records of patients diagnosed with jaundice, but no identifiable patient information will be collected.
A haemostatic composition comprises at least six parts by weight of a non-toxic water-soluble salt e.g. potassium, sodium or ammonium salt, of 3-hydroxy-2-naphthoic acid, and one part by weight of adrenochrome mono-oxime, adrenochrome mono-semicarbazone or adrenochrome isonicotinic acid hydrazone.  An aqueous solution suitable for injection is prepared by dissolving in the solution of the salt of 3-hydroxy-2-naphthoic acid having a concentration of at least one per cent by weight, at least one milligram per cc. of adrenochrome derivative.  Up to two per cent by weight of benzyl alcohol may also be incorporated in the injectable solution.  The solution may be evaporated to dryness e.g. by vacuum distillation at temperatures below 50 DEG  to 60 DEG C., lypophilization or rapid spray drying, to yield a dry preparation which may be mixed with milk, sugar or starch and tabletted. Specification 757,137 is referred to.
All patients were treated with favipiravir for a week. At the same time, the patients in this arm received Hydrogel patch (Adhesive Hydrogel patch/week, Rebul Pharmacy, Turkey) for 14 days.
Caregivers will meet in monthly 1-hour group sessions with a pediatric speech-language pathologist. The speech-language pathologist will describe strategies that families can use at home to boost their child's speech and language skills.
A critical component of animal conservation in a changing world is an understanding of the physiological resilience of animals to different conditions. In many aquatic animals, hypoxia (low environmental oxygen levels) is a regular occurrence, but the likelihood and severity of hypoxia vary across habitats. Fast-flowing, stream-like habitats are never hypoxic, so long as flow is maintained. Do animals from such habitats retain the capacity to survive hypoxic conditions? We use aquatic frog tadpoles to test the effects of natural habitat on performance in hypoxia in an experimental framework, finding that stream-living tadpoles have reduced performance in hypoxia. Tadpoles also vary in lung presence, with some species able to breathe air during hypoxia. We found that among lunged tadpoles, air-breathing rates increase in hypoxia in pond-living species but not stream-living species. Lung presence was also found to influence hypoxia performance, as lungless, stream-living tadpoles were found to be especially vulnerable to hypoxia, while pond-living, lungless tadpoles appeared largely resilient to hypoxia. We consider the ramifications of our findings on conservation outlooks and strategies for frogs and their tadpoles, suggesting that stream-living tadpoles, and especially lungless, stream-living tadpoles, may be particularly at risk to factors that reduce stream flow. Thus, a primary goal for conservation and management of species with stream-living tadpoles should be the maintenance of year-round streamflow, which oxygenates waters and prevents hypoxia.
The invention discloses application of metallothionein serving as prepared medicine for acupuncture point mediated treatment of type II diabetes and complications thereof. The metallothionein refers to freeze-dried powder rabbit liver metallothionein with the purity of more than 95 percent. The metallothionein (MT) serving as a strong antioxidant and a metal ion buffer agent is applied to treating the type II diabetes and complications thereof. The in-vivo and lesion wastes are eliminated, namely the free radicals are eliminated, target cell substances with resistant or immunization on insulin are eliminated, command signal smoothness of in-vivo insulin on the target cells is realized, the injured DNA is repaired, the pH value of the body fluid is improved, and normal pinocytosis functions of the cells on glucose are restored. The metabolism of overall organs or tissues is obviously improved, the diseases are cured, and the complications can be obviously eliminated or alleviated. The status of the traditional Chinese medicine in treatment of the type II diabetes and complications thereof is improved, and huge social effects and economic benefits are achieved.
The inventors propose that individuals with certain allotypes (e.g. the G1m(3) allotype) which bind the HSV-1 FcR with lower affinity than other allotypes, are better protected against HSV-1 infection than those with higher affinity allotypes (e.g. the G1m(1,17) allotype). Therefore there are provided methods for choosing an appropriate allotype(s) of an immunoglobulin for the treatment or prevention of an infection in which a pathogen causes expression of a heterologous FcR. The appropriate Fc of the immunoglobulin chosen can then be engineered together with a suitable specificity (ligand) for pathogen, pathogen infected cell or the FcR encoded by the pathogen. In particular it is proposed selection, design, production and/or administration of immunoglobulins of allotypes which bind HSV-1 and other heterologous FcRs with modified affinity.
The invention provides an application of a Geranium wilfordii Maxim. aqueous extract in the preparation of anti-angiogenesis drugs. The anti-angiogenesis effect of the Geranium wilfordii Maxim. aqueous extract is found in the invention for the first time. In vivo pharmacodynamic experiments using a zebra fish angiogenesis model confirm that the Geranium wilfordii Maxim. aqueous extract can substantially inhibit angiogenesis of zebra fish, so the Geranium wilfordii Maxim. aqueous extract has anti-angiogenesis activity, can be used as an angiogenesis inhibitor, and can be applied in treatment of tumors, arthritis, skin and ophthalmologic diseases, atherosclerosis, vascular dementia, endometriosis and other angiogenesis-dependent and angiogenesis-related diseases.